8-K: Arcus Biosciences Reports Second Quarter 2024 Financial Results and Provides Pipeline Update

Arcus Biosciences announced its second quarter 2024 financial results, highlighted by $1.0 billion in cash and progress across its oncology pipeline.

Summary

• Arcus Biosciences reported its financial results for the second quarter of 2024, ending June 30, 2024.
• The company has $1.0 billion in cash, cash equivalents, and marketable securities, which they expect will fund operations into 2027.
• Revenues for the quarter were $39 million, compared to $29 million in the same period of 2023.
• Research and development expenses were $115 million for the quarter, up from $84 million in the same period of 2023.
• The net loss for the quarter was $93 million, compared to a net loss of $75 million for the same period in 2023.
• The company is advancing multiple clinical programs, including casdatifan, domvanalimab, and quemliclustat.
• Patient enrollment has completed for the Phase 3 study STAR-221 for domvanalimab plus zimberelimab and chemotherapy in upper gastrointestinal cancers.
• Arcus expects to present data from the casdatifan 100 mg expansion cohort of ARC-20 in the fourth quarter of 2024.
• The Phase 3 study PEAK-1, evaluating casdatifan in combination with cabozantinib, is expected to begin in the first half of 2025.
• Taiho Pharmaceutical exercised its option for quemliclustat in Japan and certain other territories in Asia, triggering an opt-in payment and potential near-term milestone payments for Arcus.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial backing, promising clinical trial results, and strategic collaborations. While there are increased expenses and a net loss, the overall tone is optimistic due to the company's progress and future prospects.

Positives

• Arcus has a strong cash position of $1.0 billion, ensuring funding into 2027.
• Revenues increased by $10 million compared to the same quarter last year.
• The company is making significant progress in its clinical pipeline with multiple data readouts expected in the near future.
• The completion of enrollment for the STAR-221 study is a positive milestone.
• The exercise of the option for quemliclustat by Taiho provides financial benefits and validation of the program.
• The 19.7 month median overall survival in the ARC-9 study is a significant achievement.
• The 12.9 month median progression-free survival in the EDGE-Gastric study exceeds historical benchmarks.

Negatives

• The net loss for the second quarter of 2024 increased to $93 million from $75 million in the same period of 2023.
• Research and development expenses increased by $31 million compared to the same quarter last year.
• General and administrative expenses also increased slightly compared to the same quarter last year.

Risks

• The company's success is dependent on the outcome of clinical trials, which are subject to inherent risks and uncertainties.
• There are risks associated with preliminary and interim data not being guarantees that future data will be similar.
• The company is dependent on collaborations with third parties like Gilead and Taiho.
• There are risks associated with the management of the collaboration activities or expanded clinical programs.
• Changes in the competitive landscape for Arcus's programs could impact the company's success.
• The company faces the inherent uncertainty associated with pharmaceutical product development and clinical trials.

Future Outlook

Arcus expects its current cash position to fund operations into 2027 and anticipates multiple data presentations and study initiations in the coming months and years. The company is also actively planning for future studies and collaborations.

Management Comments

• Our upcoming presentation of efficacy and safety data for casdatifan will demonstrate that it has the potential to be the best-in-class HIF-2a inhibitor, said Terry Rosen, Ph.D., chief executive officer of Arcus.
• We are pursuing a broad development program in both firstand second-line settings, as well as differentiated combinations, to maximize the opportunity for casdatifan in ccRCC.
• The accumulating data continue to enhance our confidence that our Fc-silent anti-TIGIT antibody, domvanalimab, has the potential for an improved safety profile over that of Fc-enabled antibodies, particularly when combined with chemotherapy, which may also result in an efficacy advantage for domvanalimab.
• With STAR-221 enrollment completed, we are looking forward to our first Phase 3 data readout.

Industry Context

This announcement highlights Arcus's progress in the competitive oncology space, particularly in areas like TIGIT, HIF-2a, and CD73 inhibition. The company's collaborations with Gilead and Taiho are also significant in the context of industry partnerships for drug development. The results of the EDGE-Gastric study are particularly relevant as they show a potential improvement over existing treatments.

Comparison to Industry Standards

• The 12.9 month median progression-free survival (PFS) for domvanalimab plus zimberelimab and chemotherapy in the EDGE-Gastric study exceeds historical benchmarks for anti-PD-1 plus chemotherapy in first-line upper GI adenocarcinomas, suggesting a potential improvement over standard treatments.
• The 19.7 months median overall survival (OS) for the EZFB arm in the ARC-9 study is the longest reported in third-line metastatic colorectal cancer (mCRC) to date in a randomized trial, indicating a significant advancement compared to existing therapies like regorafenib.
• The company is actively comparing its results to standard of care (SOC) treatments in various trials, such as the STAR-221 study comparing domvanalimab plus zimberelimab and chemotherapy to nivolumab plus chemotherapy, and the PEAK-1 study comparing casdatifan plus cabozantinib to cabozantinib monotherapy.
• Arcus is also developing novel combinations, such as domvanalimab plus zimberelimab, which are being compared to existing treatments like pembrolizumab plus chemotherapy in the STAR-121 study for non-small cell lung cancer (NSCLC).
• The company's focus on Fc-silent antibodies, like domvanalimab, is a differentiated approach compared to some competitors using Fc-enabled antibodies, aiming for an improved safety profile.

Related Party Transactions

• Arcus recognized $28 million in license and development services revenue related to the advancement of programs, as well as $11 million in other collaboration revenue primarily related to Gileads ongoing rights to access Arcuss research and development pipeline in accordance with the Gilead collaboration agreement.
• Arcus recognized gross reimbursements of $40 million and $44 million, respectively, for shared expenses from its collaborations, primarily the Gilead collaboration.

Stakeholder Impact

• Shareholders will be encouraged by the strong cash position and progress in the clinical pipeline.
• Employees may benefit from the company's growth and development.
• Patients may benefit from the development of new cancer treatments.
• Collaborators like Gilead and Taiho will see the progress of their partnered programs.
• Creditors will be reassured by the company's financial stability.

Next Steps

• Present data from the casdatifan 100 mg expansion cohort of ARC-20 in the fourth quarter of 2024.
• Initiate the Phase 3 PEAK-1 study evaluating casdatifan in the first half of 2025.
• Present overall survival and progression-free survival data from Part 1 of the Phase 3 ARC-10 study by the end of 2024.
• Present overall survival data from the Phase 2 EDGE-Gastric study in 2025.
• Initiate the Phase 3 trial, PRISM-1, of quemliclustat in pancreatic cancer by early 2025.
• Advance AB801 into expansion cohorts in NSCLC in early 2025.
• Determine next steps for the development of etrumadenant in mCRC with Gilead.

Key Dates

Keywords

Arcus Biosciences, Oncology, Clinical Trials, Casdatifan, Domvanalimab, Zimberelimab, Quemliclustat, HIF-2a, TIGIT, CD73, A2a/A2b, Cancer, Biopharmaceutical, Gilead, Taiho